Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100S9UJ
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥443.9bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥228.6bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥66.5bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥36.8bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥66.4bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥36.6bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥1.75Tat 2023-09-30Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.66Tat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.26Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.26Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥187.3bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥53.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥36.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥30.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥67.272023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥36.992023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥67.242023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥36.972023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥119m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥84.1bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥10.6bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥265.7bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥57.6bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥94.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥8.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥443.8bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥76.6bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 690
ItemContextValueUnit
Profit loss IFRSPrior1YTDDuration40321000000JPY
Other comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember146346000000JPY
Other comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember146346000000JPY
Other comprehensive income IFRSPrior1YTDDuration146346000000JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember40321000000JPY
Comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember146346000000JPY
Comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember186667000000JPY
Comprehensive income IFRSPrior1YTDDuration186667000000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-9000000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-14405000000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-14415000000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration-14415000000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember20000000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember83000000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-103000000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember0JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration0JPY
Dividends ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-13613000000JPY
Dividends ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-13613000000JPY
Dividends ss IFRSPrior1YTDDuration-13613000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember2812000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-2812000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-8000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember123000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember38000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember153000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration153000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass